224 related articles for article (PubMed ID: 18488223)
1. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial.
Schulze T; Kemmner W; Weitz J; Wernecke KD; Schirrmacher V; Schlag PM
Cancer Immunol Immunother; 2009 Jan; 58(1):61-9. PubMed ID: 18488223
[TBL] [Abstract][Full Text] [Related]
2. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.
Schlag P; Manasterski M; Gerneth T; Hohenberger P; Dueck M; Herfarth C; Liebrich W; Schirrmacher V
Cancer Immunol Immunother; 1992; 35(5):325-30. PubMed ID: 1394336
[TBL] [Abstract][Full Text] [Related]
3. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.
Ockert D; Schirrmacher V; Beck N; Stoelben E; Ahlert T; Flechtenmacher J; Hagmüller E; Buchcik R; Nagel M; Saeger HD
Clin Cancer Res; 1996 Jan; 2(1):21-8. PubMed ID: 9816085
[TBL] [Abstract][Full Text] [Related]
4. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.
Vermorken JB; Claessen AM; van Tinteren H; Gall HE; Ezinga R; Meijer S; Scheper RJ; Meijer CJ; Bloemena E; Ransom JH; Hanna MG; Pinedo HM
Lancet; 1999 Jan; 353(9150):345-50. PubMed ID: 9950438
[TBL] [Abstract][Full Text] [Related]
5. [Adjuvant therapy of liver metastases: active specific immunotherapy].
Hagmüller E; Beck N; Ockert D; Schirrmacher V
Zentralbl Chir; 1995; 120(10):780-5. PubMed ID: 7502592
[TBL] [Abstract][Full Text] [Related]
6. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
[TBL] [Abstract][Full Text] [Related]
7. In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients.
Liebrich W; Schlag P; Manasterski M; Lehner B; Stöhr M; Möller P; Schirrmacher V
Eur J Cancer; 1991; 27(6):703-10. PubMed ID: 1829908
[TBL] [Abstract][Full Text] [Related]
8. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
Schimanski CC; Möhler M; Schön M; van Cutsem E; Greil R; Bechstein WO; Hegewisch-Becker S; von Wichert G; Vöhringer M; Heike M; Heinemann V; Peeters M; Kanzler S; Kasper S; Overkamp F; Schröder J; Seehofer D; Kullmann F; Linz B; Schmidtmann I; Smith-Machnow V; Gockel I; Lang H; Galle PR
BMC Cancer; 2012 Apr; 12():144. PubMed ID: 22494623
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Brandi G; Derenzini E; Falcone A; Masi G; Loupakis F; Pietrabissa A; Pinna AD; Ercolani G; Pantaleo MA; Di Girolamo S; Grazi GL; de Rosa F; Biasco G
Clin Colorectal Cancer; 2013 Sep; 12(3):188-94. PubMed ID: 23773458
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases.
Rudroff C; Altendorf-Hoffmann A; Stangl R; Scheele J
Langenbecks Arch Surg; 1999 Jun; 384(3):243-9. PubMed ID: 10437612
[TBL] [Abstract][Full Text] [Related]
12. Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine.
Lehner B; Schlag P; Liebrich W; Schirrmacher V
Cancer Immunol Immunother; 1990; 32(3):173-8. PubMed ID: 2289211
[TBL] [Abstract][Full Text] [Related]
13. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus.
Bohle W; Schlag P; Liebrich W; Hohenberger P; Manasterski M; Möller P; Schirrmacher V
Cancer; 1990 Oct; 66(7):1517-23. PubMed ID: 2208003
[TBL] [Abstract][Full Text] [Related]
14. Colorectal hepatic metastases: resection, local ablation, and hepatic artery infusion pump are associated with prolonged survival.
Heslin MJ; Medina-Franco H; Parker M; Vickers SM; Aldrete J; Urist MM
Arch Surg; 2001 Mar; 136(3):318-23. PubMed ID: 11231853
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer.
Ogata Y; Matono K; Tsuda H; Ushijima M; Uchida S; Akagi Y; Shirouzu K
PLoS One; 2015; 10(3):e0120064. PubMed ID: 25790229
[TBL] [Abstract][Full Text] [Related]
17. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Wasan HS; Gibbs P; Sharma NK; Taieb J; Heinemann V; Ricke J; Peeters M; Findlay M; Weaver A; Mills J; Wilson C; Adams R; Francis A; Moschandreas J; Virdee PS; Dutton P; Love S; Gebski V; Gray A; ; ; ; van Hazel G; Sharma RA
Lancet Oncol; 2017 Sep; 18(9):1159-1171. PubMed ID: 28781171
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
Schimanski CC; Kasper S; Hegewisch-Becker S; Schröder J; Overkamp F; Kullmann F; Bechstein WO; Vöhringer M; Öllinger R; Lordick F; Heinemann V; Geißler M; Schulz-Abelius A; Bernhard H; Schön MR; Greil R; Galle P; Lang H; Schmidtmann I; Moehler M
Oncoimmunology; 2020 Aug; 9(1):1806680. PubMed ID: 32923171
[TBL] [Abstract][Full Text] [Related]
19. Analysis of predictive factors for recurrence after hepatectomy for colorectal liver metastases.
Yamada H; Kondo S; Okushiba S; Morikawa T; Katoh H
World J Surg; 2001 Sep; 25(9):1129-33. PubMed ID: 11571947
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial.
Hoover HC; Brandhorst JS; Peters LC; Surdyke MG; Takeshita Y; Madariaga J; Muenz LR; Hanna MG
J Clin Oncol; 1993 Mar; 11(3):390-9. PubMed ID: 8445413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
